[18F]MNI-1126
- Generic Name
- [18F]MNI-1126
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss
Phase 1
Completed
- Conditions
- Healthy VolunteersParkinson DiseaseAlzheimer Disease
- Interventions
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Invicro
- Target Recruit Count
- 12
- Registration Number
- NCT03587649
- Locations
- 🇺🇸
Invicro, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath